Genomic Health Announces Fourth Quarter and Year-end 2005 Financial Results and Business Progress

REDWOOD CITY, Calif., Feb 13 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results for the fourth quarter and year ended December 31, 2005.

Total revenue increased to $1.9 million in the fourth quarter of 2005 versus $0.1 million in the fourth quarter of 2004 and $1.6 million in the third quarter of 2005. Total revenue for the year ended December 31, 2005 increased to $5.2 million versus $0.3 million in 2004. These increases were driven primarily by increased adoption and reimbursement for Oncotype DX(TM), the Company's test that quantifies the likelihood of breast cancer recurrence and predicts the likelihood of response to chemotherapy in early-stage breast cancer patients.

Product revenue from Oncotype DX increased to $1.9 million in the fourth quarter of 2005 compared to $0.1 million in the fourth quarter of 2004 and $1.4 million in the third quarter of 2005. Product revenue was $4.8 million for the year ended December 31, 2005 compared to $0.2 million in 2004. Product revenue was recognized as cash is collected for test results delivered unless a preset arrangement and a history of payment exists. During the fourth quarter of 2005, 17 percent of product revenue was recorded on an accrual basis and recognized at the time the test result was delivered for those payors where a contract and a demonstrated history of payment were in place. Contract revenue was $0.1 million in the fourth quarter of 2005 compared to no contract revenue in the fourth quarter of 2004, and $0.4 million of contract revenue for the year ended December 31, 2005 compared to $0.1 million in 2004.

"In 2005, we made steady progress in bringing individualized medicine to clinical practice through our Oncotype DX breast cancer assay. Highlights of the year included multiple presentations and peer-reviewed publications of clinical studies demonstrating the utility and value of Oncotype DX, as well as improvement in obtaining reimbursement from significant payors," said Randy Scott, Ph.D., Chairman and Chief Executive Officer of Genomic Health. "We also expanded our pipeline of future potential tests in breast and other cancers, and are currently working with respected cooperative study groups, institutions and pharmaceutical partners to conduct studies designed to enhance the quality of treatment decisions for patients with cancer."

"Physician usage and adoption of Oncotype DX is building, with more than 2,100 test results delivered in the fourth quarter and more than 7,000 test results delivered during 2005, up from over 550 in all of 2004," said Kim Popovits, President and Chief Operating Officer of Genomic Health. "More than 2,400 physicians have ordered at least one test for treatment planning decisions with their patients since launch, and more than half of these physicians have ordered multiple tests. In 2006, we plan to continue to execute on our strategy of driving physician usage and adoption of Oncotype DX and increasing the clinical evidence supporting the utility of Oncotype DX."

Additional Fourth Quarter 2005 Financial Results

For the first time, product revenue exceeded cost of product revenue. Cost of product revenue was $1.7 million for the fourth quarter of 2005, compared to $0.6 million in the fourth quarter of 2004. While this increased cost reflects higher testing volume in 2005 versus 2004, the cost per test decreased in the fourth quarter of 2005 compared to both the fourth quarter of 2004 and the third quarter of 2005. Research and development expenses for the fourth quarter of 2005 were $2.5 million compared to $2.4 million for the same period in 2004. The slight increase was due to higher personnel costs and research programs in 2005 as compared to higher collaboration expense and license fees in the fourth quarter of 2004.

Selling and marketing, and general and administrative expenses for the fourth quarter of 2005 were $6.5 million, compared to $4.3 million for the same period in 2004. This increase is primarily due to costs associated with marketing of Oncotype DX, investment in the commercial field sales team, higher billing and collection costs and costs associated with being a public company.

Net loss was $8.2 million in the fourth quarter of 2005 compared to $7.1 million in the fourth quarter of 2004. Basic and diluted net loss per share applicable to common stockholders was $0.34 in the fourth quarter of 2005 compared to $3.68 net loss per share in the fourth quarter of 2004. On a pro forma basis, basic and diluted net loss per share was $0.34 for the fourth quarter of 2005 compared to $0.44 net loss per share for the same period in 2004. The pro forma and diluted net loss per share calculations assume the conversion of all outstanding shares of preferred stock into shares of common stock using the as-if-converted method as of January 1, 2004 or the date of issuance, if later.

Additional Financial Results for Year Ended December 31, 2005

Cost of product revenue for the year ended December 31, 2005 was $6.2 million compared to $1.8 million in 2004. These increased costs represent higher test volume in 2005. Research and development expenses in 2005 were $9.5 million as compared to $10.0 million in 2004. Selling and marketing and general and administrative expenses in 2005 were $21.8 million compared to $13.7 million in 2004.

Net loss for the year ended December 31, 2005 was $31.4 million compared to $25.0 million in 2004. Basic and diluted net loss per share was $4.18 for the year ended December 31, 2005 compared to $13.82 net loss per share in 2004. On a pro forma basis, basic and diluted net loss per share was $1.31 per share for the year ended December 31, 2005 versus $1.62 net loss per share for the same period in 2004.

Cash and Cash Equivalents

Cash and cash equivalents and investments at December 31, 2005 were $69.5 million, compared to $38.3 million at December 31, 2004 and $17.2 million at September 30, 2005. In the fourth quarter of 2005, the net proceeds of $53.5 million from the Company's initial public offering were received, and an additional $5.0 million was received from a private sale of common stock to Incyte Corporation.

  Recent Highlights and Accomplishments

   --   Peer-Reviewed Publications and Medical Meeting Presentations
        --   Researchers from Rocky Mountain Cancer Center in Denver,
             Colorado presented data at the December 2005 San Antonio Breast
             Cancer Symposium (SABCS) showing that Oncotype DX, when added
             to other clinical decision parameters, such as age and tumor
             grade, changed treatment decisions in 25 percent of the 68
             patients studied.

        --   Our collaborators at the National Surgical Adjuvant Breast and
             Bowel Project (NSABP) -- a National Cancer Institute-funded
             cooperative group -- demonstrated that Oncotype DX also
             predicts local recurrence in addition to distant recurrence as
             previously had been reported in women with node-negative,
             estrogen receptor-positive breast cancer. Researchers from
             Genomic Health and the Royal Marsden Hospital in London also
             reported that successful gene expression analysis from very
             small fixed-paraffin-embedded tumor specimens was feasible
             using the Oncotype DX 21-gene panel. These studies were
             presented at the SABCS in December, 2005.

        --   An exploratory study in patients with node-positive breast
             cancer conducted at Rush-Presbyterian Hospital in Chicago was
             published in the December 2005 issue of Clinical Cancer
             Research. The study demonstrated that a number of genes
             correlated with recurrence in patients with 10 or more positive
             lymph nodes, including multiple genes included in the Oncotype
             DX breast cancer assay.

   --   Physician Usage and Adoption
        --   More than 2,400 physicians had used Oncotype DX through year
             end.

        --   Over 2,100 test results were delivered in the fourth quarter of
             2005 and over 7,000 in all of 2005, approximately 15 percent of
             which were for Medicare patients.

   --   Reimbursement Progress
        --   In the fourth quarter of 2005 the Federal Employees Health
             Benefits Program (FEHBP) instituted a positive reimbursement
             policy for Oncotype DX.  FEHBP covers about 8 million lives and
             is administered through numerous regional healthcare plans.
             The largest of these, Blue Cross and Blue Shield Federal
             Employee Plan, which covers about 5 million lives within FEHBP,
             has signed a letter of agreement to reimburse Oncotype DX.

        --   In December 2005, an administrative law judge overturned 146 of
             171 Medicare denials in favor of Oncotype DX, ruling that the
             test was safe and effective.

        --   In January 2006, Blue Cross and Blue Shield of Alabama posted a
             positive coverage decision for Oncotype DX.

        --   In January 2006, Medicare's California contractor, National
             Heritage Insurance Company, established a positive coverage
             policy for Oncotype DX.  This policy is expected to apply to
             Medicare patients whose samples are processed at our CLIA-
             certified, CAP-accredited laboratory in Redwood City,
             California.  The policy is scheduled to take effect February
             27, 2006.

        --   In early February 2006, we obtained our first reimbursement
             coverage outside of the U.S. for certain international
             patients. Clalit Health Care, the largest government payor in
             Israel, covering 60 percent of the population, will provide
             reimbursement coverage of Oncotype DX for their patients.
             Oncotype DX is currently offered for sale in Israel under a
             testing and services agreement with Teva Pharmaceutical
             Industries Ltd. Tests ordered in Israel are processed in our
             Redwood City, California central reference laboratory.

   --   Pharmaceutical and Cooperative Study Group Collaborations
        --   The Company recently entered into a collaborative agreement
             with sanofi-aventis and the Eastern Cooperative Oncology Group
             (ECOG) to investigate the ability of gene expression in fixed-
             paraffin-embedded tissues to predict the likelihood of response
             to adjuvant chemotherapy, including Taxotere(R), in patients
             with early breast cancer and zero to three involved lymph
             nodes. The agreement provides Genomic Health with commercial
             rights to diagnostic tests that result from the collaboration.

   --   Other
        --   The Company recently announced that it would meet with the Food
             and Drug Administration at the FDA's invitation to discuss the
             nature and regulatory status of Oncotype DX.

  2006 Financial Guidance

The Company is providing the following financial guidance for the full year ending December 31, 2006:

   --   Test Results Delivered: Approximately 12,000.
   --   Revenue: $14 million to $18 million.
   --   Net Loss: $37 million to $43 million.

  Conference Call Details

To access the live conference call today, February 13 at 4:30 p.m. Eastern Time via phone, please dial (877) 356-8064 from the United States and Canada or (706) 758-4314 internationally. The conference ID is 5085638. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through February 20 and may be accessed by dialing (800) 642-1687 from the United States and Canada or (706) 645-9291 internationally. The replay passcode is 5085638.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the Company's website at http://investor.genomichealth.com/ . Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

About Oncotype DX and Genomic Health

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early stage breast cancer patients. The Oncotype DX assay represents the first diagnostic gene expression test on the market that provides consistent results across multiple independent trials involving more than 2,600 breast cancer patients, including a large validation study published in the December 30, 2004 edition of The New England Journal of Medicine. For more information about Oncotype DX, go to http://www.oncotypedx.com/ or http://www.genomichealth.com/.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our ability to execute our strategy, market sizes and trends, the circumstances which may result in increased physician use or acceptance of our products, the factors that may contribute to positive coverage or reimbursement decisions, the results of, or progress in, our clinical studies, the applicability of clinical study results to actual outcomes, the results of our collaborative arrangements, the status of regulation by the U.S. Food and Drug Administration (FDA) of our products, the scope or effectiveness of coverage decisions, our ability to develop diagnostic tests as a result of collaborative arrangements and our future financial results. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our ability to increase usage of our test; our ability to develop and commercialize new products; the risk of unanticipated delays in research and development efforts; the risk that we may not obtain reimbursement for our existing test and any future products we may develop; the risks and uncertainties associated with the regulation of our products by the FDA; our ability to compete against third parties; our ability to obtain capital when needed; our history of operating losses and the other risks set forth in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2005. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

                             Genomic Health, Inc.
               Condensed Consolidated Statements of Operations
               (in thousands, except share and per share data)

                           For the Three Months Ended  For the Year Ended
                                   December 31,            December 31,
                                 2005        2004        2005        2004
                                    (Unaudited)      (Unaudited) (Audited)

  REVENUE:
  Product revenue               $1,863        $127      $4,823       $227
  Contract revenue                  62          --         379        100

  Total revenue                  1,925         127       5,202        327

  OPERATING EXPENSE:
  Cost of product revenue        1,729         554       6,249      1,828
  Research and development       2,494       2,436       9,465     10,040
  Selling and marketing          4,543       3,106      15,348      9,856
  General and administrative     1,974       1,180       6,485      3,869
  Total operating expenses      10,740       7,276      37,547     25,593

  Operating loss                (8,815)     (7,149)    (32,345)   (25,266)

  Other income (expense):
  Interest income                  693          90       1,241        295
  Interest expense                 (95)         --        (258)        (4)

  Other income                      --          --           1        (20)

  Net loss                     ($8,217)    ($7,059)   ($31,361)   ($24,995)

  Basic and diluted
   net loss per share           ($0.34)     ($3.68)     ($4.18)    ($13.82)

  Shares used to compute
   basic and diluted net
   loss per share           23,904,747   1,916,275   7,499,982   1,808,022

  Pro forma basic and
   diluted net loss
   per share                    ($0.34)     ($0.44)     ($1.31)     ($1.62)
  Shares used to compute
   pro forma basic and
   diluted net loss
   per share                24,455,518  16,078,171  23,991,612  15,442,326


                             Genomic Health, Inc.
                    Condensed Consolidated Balance Sheets
                                (in thousands)

                                           As of              As of
                                     December 31, 2005  December 31, 2004
                                         (Unaudited)         (Audited)
  Cash and cash equivalents               $18,839            $38,275
  Short term investments                   50,688                 --
  Prepaid expenses and
   other current assets                     1,935                976
  Total current assets                     71,462             39,251

  Property and equipment, net               3,597              2,116
  Restricted cash                             500                 --
  Other assets                                240                171
  Total assets                            $75,799            $41,538

  Accounts payable                         $1,393             $1,101
  Other current liabilities                 2,978              1,379
  Deferred revenue                            238                 --
  Capital leases, short-term                1,052                 --
  Capital leases, long-term                 2,621                 --
  Stockholder's equity                     67,517             39,058
  Total liabilities and
   stockholders' equity                   $75,799            $41,538

FCMN Contact: daryl@weisscom.net